Drug - target binding and Ligand Binding Assays (LBA)

Drug - target binding and Ligand-binding assays (LBA) are commonly used within the scope of Pharmacodynamic (PD) assessments to quantify the binding capacity of biologics to their respective targets. In addition, Ligand-binding assays are key tools for Pharmacokinetic (PK) / Toxicokinetic (TK) evaluations and the assessment of Immunogenicity of biologic drugs. IBR Inc. is experienced in development, validation and operation of ligand-binding assays in compliance with the GxP quality standards. We support your projects from pre-clinical to clinical development.

Our Technologies

With our state-of-the-art technology platforms, we provide a broad spectrum of cell-based or non cell-based ligand-binding assays.
Our experienced scientists advise you on selecting the most suitable assay format to ensure robust and reliable data.
Flow Cytometry is the method of choice for detection ligand-binding interactions on the cell-surface.
Our advanced Immuno-Assay Technologies are designed for increased sample throughput and combine minimal samples volumes with highest sensitivity at retained robustness.

Our multimode Microplate Readers allow for classical detection of ligand-binding interactions by measurement of absorbance and fluorescence.

For Ligand Binding Assays that require very high sensitivity we leverage

  • TRF (Time-Resolved Fluorescence), including Delfia
  • TR-FRET (Time-resolved fluorescence energy transfer), including HTRF (homogenous TRF) cell-based assays and Lance

In addition, we provide classical ELISA and ELISpot.

 

Submit a Question or Request
 

Simply fill out the form below and a member of our team will follow up with you shortly.

 

I accord my agreement for the usage and processing of my personal data for the purpose of processing my inquiry (see Privacy Policy). I am aware that I have the right to object the processing of my data at any time and with effect for the future.